The Multaq Sanofi wins a major recommendation
Posted by admin | Under business success, corporations, facts, occupation, work Sunday Aug 29, 2010The Sanofi-Aventis Multaq must be considered one of the main options for treating atrial fibrillation, one of the most frequent disorders of cardiac rhythm, recommended on Sunday the European Society of Cardiology (ESC).
This recommendation is a key support rider for a drug that has so far achieved only modest commercial start.
The Multaq (dronedarone) is intended to replace an older molecule, amiodarone, and has fewer risk factors than the latter, but it has generated to date that relatively weak sales in the U.S. and Europe because several studies have found limited effectiveness.
In its new recommendations on the management of atrial fibrillation (AF), ESC Multaq attributed to a Class 1 recommendation, which means it is a safer treatment option even though it may be less effective.
"Given the superior advantages in terms of safety and potential outcomes, the dronedarone might be preferable as a first option antiarrhythmic" explain the recommendations, published at the ESC congress in Stockholm.
The paper also highlights, for the first time the importance of reducing the duration of hospitalization of patients with atrial fibrillation, a result of Multaq found in a pivotal clinical trial.
The drug is not recommended for patients with severe heart weakness.
"Sanofi-Aventis is pleased with this recommendation Multaq first line in the FA, which constitutes a recognition of the extensive clinical development program of the drug and the innovative results achieved in terms of reduced hospitalizations from cardiovascular causes," said Marc Cluzel, executive vice president in charge of research and development in the pharmaceutical group, in a statement.
The marketing of Multaq was approved in the United States in July 2009 and last September in the European Union.He is considered one of the main growth potential of Sanofi for years to come, which will be marked by the patent expiry of several key products groups, which include cancer Taxotere or anticoagulant Plavix.
The Multaq could generate an annual turnover of 1.2 billion euros in 2014 according to consensus estimates of analysts by Thomson Reuters.